Listen "Clinical Insight: Engaging PWID in HCV Care"
Episode Synopsis
People who inject drugs (PWID) comprise a rapidly growing population of HCV-infected people who have historically been difficult to reach and treat. But without engagement in HCV care, PWID will continue to transmit the virus and impede efforts for hepatitis C eradication.In this issue, Dr. Arthur Kim from Massachusetts General Hospital and Harvard Medical School provides a clinical perspective on identifying and overcoming the barriers that prevent PWID from effectively receiving HCV treatment.Take our post-test to claim CME credits.To read a companion newsletter click here. Hosted on Acast. See acast.com/privacy for more information.
More episodes of the podcast eViralHepatitis Review
Medications for CHB
20/10/2022
To Treat or Not To Treat
20/10/2022
HBV & Coinfections
20/10/2022
Hepatitis B: Our Current Understanding
20/10/2022
HBV: Next Steps to a Cure
03/08/2021
Treating HCV in PWID: Best Practices
10/04/2020
HCV: Management Beyond the Liver
04/03/2020
Avoiding “MELD Purgatory”
19/04/2019